Over the past 30 years, tremendous progress has been made in the treatment of cancer, increasing the number of cancer survivors in the US from 3 to nearly 12 million. However, an increasing number of cancer survivors are developing second, therapy-related cancers, in particular therapy-related acute myeloid leukemia (t-AML). The disease is a direct result of mutational events induced by chemotherapy or radiotherapy used in the treatment.
Learn more . . .

The Cancer Research Foundation and the University of Chicago Comprehensive Cancer Center are developing a unique program to fight therapy-related leukemia. Learn more . . .